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Abstract
Objectives—To develop an integrated metric of non COX-1 dependent platelet function
(NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics.
Background—NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1.
Although a variety of NCDPF assays are available, no standard exists and their reproducibility is
not established.
Methods—We administered 325mg/day aspirin to two cohorts of volunteers (HV1, n = 52, and
HV2, n = 96) and diabetics (DM, n = 74) and measured NCDPF using epinephrine, collagen, and
ADP aggregometry and PFA100 (collagen/epi) before (Pre), after one dose (Post), and after
several weeks (Final). COX-1 activity was assessed with arachidonic acid aggregometry (AAA).
The primary outcome of the study, the platelet function score (PFS), was derived from a principal
components analysis of NCDPF measures.
Results—The PFS strongly correlated with each measure of NCDPF in each cohort. After two or
four weeks of daily aspirin the Final PFS strongly correlated (r > 0.7, p<0.0001) and was higher (p
< 0.01) than the Post PFS. The magnitude and direction of the change in PFS (Final - Post) in an
individual subject was moderately inversely proportional to the Post PFS in HV1 (r = −0.45), HV2
(r = −0.54), DM (r = −0.68), p<0.0001 for all. AAA remained suppressed during aspirin therapy.
Conclusions—The PFS summarizes multiple measures of NCDPF. Despite suppression of
COX-1 activity, NCDPF during aspirin therapy is predictably dynamic: those with heightened
NCDPF continue to decline whereas those with low/normal NCDPF return to pre-aspirin levels
over time.
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Introduction
Aspirin is the most commonly prescribed medication for the prevention of cardiovascular
disease.[1] In both research and clinical settings the response to aspirin is measured using ex
vivo platelet function testing.[2] Although widely used, there are limitations to this approach
to measure an inhibitory response to a common drug like aspirin.[2] First, although variety
of assays is available and light transmittance aggregometry (LTA) is the most commonly
used platform, the optimal platform has not been defined.[2] Second, various stimuli can be
employed; however, the optimal agonist or concentration has not been determined.[2]
Finally, although a heightened aggregatory response to agonists, including epinephrine,
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ADP, or collagen is a reproducible trait[3], prior studies of the consistency of the response to
aspirin response over time have been limited to small sample sizes[4], retrospective analyses
of aggregation data collected during clinical care[5] or were focused on platelet COX-1
activity[6]. Strategies to overcome these uncertainties must be resolved if ex vivo assays are
to be used in clinical practice. Therefore, we sought to employ an integrated measurement of
platelet function to measure the response to aspirin and investigate temporal changes in
platelet function.
Aspirin is a potent inhibitor of COX-1 and an inhibitor of platelet function. When assays
that are entirely dependent on platelet COX-1 are used (i.e., COX-1 dependent platelet
function assays such as arachidonic acid aggregation [AAA] and serum thromboxane B2),
there is minimal variation and near complete suppression of platelet function using 81–
325mg aspirin doses.[7,8] Therefore, although such COX-1 dependent tests may best
represent the biochemical response to aspirin, these may not provide a complete assessment
of platelet function on aspirin since the production of thromboxane is but one pathway
involved in platelet activation.[8]
Agonists such as collagen, epinephrine, and ADP can also stimulate platelet function
through the generation of thromboxane. However, these assays are characterized by wide
interindividual variability despite complete suppression of COX-1 activity[7,8] with aspirin
and are independently associated with cardiovascular events in patients taking aspirin[9].
Therefore, these non COX-1 dependent platelet function (NCDPF) assays are important
measures of the response to aspirin. However, no single agonist is sufficient to describe the
platelet function response to aspirin, because, in vivo, platelets are presented with multiple
stimuli. Therefore, for researchers studying platelet function or clinicians interested in the
response to aspirin therapy it would be desirable to develop a single metric that integrates
multiple NCDPF test results. Further, such an integrative metric may overcome some of the
non-biologic variability associated with platelet function testing.
With the goal of developing a single metric that integrates multiple non-COX1 dependent
platelet function (NCDPF) test results, we employed a principal components analysis to
NCDPF data from an aspirin challenge study in healthy volunteers to derive a summary
metric of platelet function that we term the platelet function score (PFS) and validated the
PFS in independent cohorts of healthy volunteers and diabetics. To demonstrate the utility of
the PFS, we 1) compared COX-1 vs. non-COX-1 dependent measures of platelet function
and 2) investigated the reproducibility and time-dependent effects of NCDPF during daily
aspirin therapy.
Methods
Aspirin challenge study -- overview
The Duke Clinical Research Unit (DCRU) and the Duke Institute for Genome Sciences &
Policy (IGSP) coordinated several aspirin challenge studies from February 2009 to May
2011. The purpose of these ongoing studies is to examine gene expression profiles in healthy
volunteers and diabetics at the extremes of platelet function in response to aspirin. The study
design and sample sizes were therefore chosen for the purposes of analyzing gene
expression data, not platelet function in response to aspirin per se. Nevertheless, this report
represents a summary of the platelet function observations made as a part of these ongoing
studies. An overview of the different cohorts and time points are described in Figure 1. We
began with a pilot study of healthy volunteers (HV1). After the completion of this pilot
study, we amended our study protocol for two subsequent studies in healthy volunteers and
diabetics (HV2 and DM): increased duration of aspirin exposure, increased age requirement,
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addition of arachidonic acid aggregation with and without in vitro aspirin, and a focus on
those at the extremes of platelet function response.
For this study, the HV2 and DM cohorts serve as independent validation cohorts for the
observations made in HV1.
From February through May 2009 a group of healthy adult volunteers (HV1) were recruited
through advertisements and had a defined set of platelet function measurements (described
below) made before aspirin (Pre), and 3-hours after (Post) a single 325mg tablet of aspirin.
Subsequently, subjects were returned for a final assessment (Final) 2 weeks after 325mg/day
aspirin. This dose of aspirin was chosen to ensure complete suppression of platelet COX-1
activity in each participant.[8]The 3-hour timepoint was chosen because we were interested
in measuring the maximal inhibitory effect of aspirin[6].
The platelet function score (PFS, described below) was derived from a principal components
analysis (PCA) of all platelet function measurements made in the HV1 cohort. From
November 2009 through July 2011 we expanded our studies to diabetics, however in order
to have a group of healthy volunteers whose age was similar to those of diabetics, we
increased the age restriction to 30 years. This second group of healthy volunteers (HV2) and
diabetics (DM) were recruited and assessed with an identical set platelet function measures
made as in HV1 before (Pre) and 3-hours after (Post) a 325mg aspirin dose. Using their
platelet function data we then calculated a PFS for each subject. The first 10 subjects in HV2
and DM were used to define the PFS distribution for each cohort, were selected to continue
with 4 weeks of aspirin therapy, and returned for a final measurement of platelet function
(Final). For subsequent subjects in the HV2 and DM cohorts, we selected those in the 1st and
4th quartile of their respective PFS distribution for additional aspirin therapy and final
platelet function testing (Final).
Inclusion and exclusion criteria
This study included healthy volunteers greater than 18 (HV1) or 30 (HV2) years old;
diabetics (defined by chart review and/or use of insulin or oral agent) must have been greater
than 30 years of age. The following exclusion criteria applied to all cohorts: history of a
bleeding disorder, gastrointestinal bleeding, regular use of antiplatelet agents (except aspirin
in DM), nonsteroidal anti-inflammatory agents (NSAIDs), oral corticosteroids,
anticoagulants, coexisting conditions: diabetes (except for HV1 and HV2), coronary artery
disease, peripheral artery disease, cerebrovascular disease, history of stroke, deep venous
thrombosis, transient ischemic attack, daily use of more than 1 prescription medication (for
HV1 and HV2, except oral contraceptives and antihistamines), regular cigarette use (defined
as > 1 cigarette/day), or known pregnancy.
Throughout the study period subjects were reminded to refrain from any new medications
(in particular those containing aspirin or NSAIDs) and cigarette use. Subjects were given a
list of over the counter medications that contain aspirin/NSAIDs to avoid. Dietary
supplements were not an exclusion criteria and were not recorded, but instead, subjects were
instructed to not alter their intake of any supplements throughout the study period. All study
participants provided informed consent. The study protocol was approved by Duke
University’s Institutional Review Board.
Aspirin and NSAID washout
For subjects taking aspirin or NSAIDs prior to entry into the study, the subject was asked to
reschedule their visit after at least 14 days of documented aspirin/NSAID abstinence.
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Aspirin therapy
Medication adherence was a priority and subjects were required to record the date and time
of each aspirin dose. Adherence was confirmed with a pill count at the end of the study.
Finally, subjects received telephone reminders during the study to ensure adherence.
Subjects that missed any of the three doses prior to the Final visit were given additional
aspirin and rescheduled until adherence was established.
Platelet function studies
Before each visit, subjects were asked to fast and to refrain from tobacco (during the
preceding 24 hours) and alcohol or intensive exercise on the day of testing. Phlebotomy was
performed after 10 minutes of resting supine with minimal trauma or stasis at the
venipuncture site using a 21-guage needle into 3.2% sodium citrate tubes. The focus of these
studies was around NCDPF and thus, we defined the NCDPF assays as the following:
PFA100, and epinephrine, ADP, and collagen induced LTA. COX-1 dependent platelet
function was initially not measured in HV1, however after observing the changes in NCDPF
in HV1, we added COX-1 dependent measures to HV2. We chose serum thromboxane B2
and AA induced aggregation as measures of COX-1 activity and also added in vitro aspirin
to the AA aggregation assay to further assess for any evidence of unsuppressed COX-1
activity.
Light transmittance aggregometry—Light transmittance aggregometry (LTA) was
performed according to the method of Born[10] and the following agonists: arachidonic acid
(AA, Chrono-log, 0.5 mM), epinephrine (Chrono-Log, 10, 1, and 0.5 uM), ADP (Chrono-
Log, 10, 5, and 1 uM), and collagen (Chrono-Log, 5 and 2 ug/ml). We chose the area under
the LTA curve (AUC) as the primary measure of aggregation because the AUC captures
several features of the aggregometry curve that are each sensitive to the effects of aspirin:
slope[11,12], maximal aggregation[13], and final aggregation[14]. To standardize AUC
measurements across individuals and visits we fixed the test duration at 12 minutes for
epinephrine and six minutes for collagen, AA, and ADP. Further description of the AUC
measurement is in the Supplemental Material.
Platelet Function Analyzer—PFA100 closure time with the use of the collagen/
epinephrine cartridge was performed as previously described by our laboratory.[15] We did
not select the collagen/ADP cartridge because its results are not sensitive to the effects of
aspirin.[16] Briefly, citrated whole blood was placed in the PFA100 chamber and blood was
aspirated through an aperture in a collagen/epinephrine coated membrane. The amount of
time (in seconds[s], up to a maximum of 300 s) until blood ceased to flow through the
membrane aperture was recorded as the final result.
Serum Thromboxane B2—Serum thromboxane B2 was measured in HV2 at the Final
visit according to the method of Patrono[17]. Briefly, serum was collected by allowing
whole blood to clot at 37 degrees Celsius for 45 minutes then centrifuged at 3000 rpm for 10
minutes. Serum was aspirated and stored at −80 degrees Celsius until ELISA testing.
Thromboxane B2 measurements were performed using an ELISA based assay, in duplicate,
averaged, and according to the manufacture’s protocol (Enzo Life Sciences, Catalog No.
ADI-900-002) with no modifications.
In vitro aspirin—A stock solution of aspirin was created by dissolving acetylsalicylic acid
(Sigma-Aldrich A5376) into DMSO and aliquots stored at −80 degrees Celsius. On the day
of use, fresh aliquots were thawed, diluted in PBS, and stored at 4 degrees Celsius. This
diluted aspirin solution was added to PRP to a final concentration of aspirin (53 uM) that
exceeds that achieved in vivo with a 325mg aspirin dose[18] or required to maximally
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inhibit arachidonic induced aggregation[19]. The PRP was allowed to incubate with in vitro
aspirin for 10 minutes at room temperature prior to the addition of agonist.
Statistical Analysis
Correlations between the various measures of platelet function were assessed with the
Spearman correlation coefficient (r). Paired or unpaired t-tests were employed to compare
continuous variables between groups and the Wilcoxon signed rank test was used for
variables that were not normally distributed. Chi square tests were used to compare
categorical variables between groups.
Missing Data—A small number of time-points (n = 21, 5%) in the collagen LTA data
were missing and were imputed in the following manner: 1) Replace the missing values by
the average for that assay. 2) Compute principal components. Let x be the NxP-dimensional
matrix of platelet function measurements, where N is the number of samples and P is the
number of different platelet function measurements. Compute the singular value
decomposition: x = UDV′. We then compute D* by setting to zero all but the first three
diagonal elements of D. 3) Compute x* = UD*V′ and replace all missing values of x with
the corresponding values from x*. 4) Repeat steps 2 and 3 until the algorithm converges.
Principal Components Analysis—Our main interest was in studying NCDPF since
others have shown minimal variation in COX-1 dependent platelet function measures on
aspirin.[13] Because we observed linear relationships between the multiple measures of
NCDPF (Table 2), we assumed that each measure of NCDPF was a reflection of a single
biological factor and thus chose a principal components analysis (PCA) to quantify this
biological factor. PCA is an unbiased, mathematical technique for reducing a collection of
measurements down to a single “meta-measurement” that best describes the aggregate
behavior of the set. For example, in the biological sciences, PCA can quantify population
substructure in genome wide association studies[20], patterns of gene expression in
microarray experiments[21], and metabolic pathways in metabolomic studies[22]. In the
present study, the input into the PCA was the following set of non-imputed measures from
the HV1 cohort: the PFA100 closure time and the AUC from each concentration of ADP,
epinephrine, and collagen LTA. Each measurement was given equal weight and we defined
the first principal component, which we constructed to be positively correlated with higher
NCDPF, as the platelet function score (PFS).
To calculate PFS in a new sample we applied the weights from the PCA performed in HV1
and the new platelet function measurements (i.e., in HV2, DM, and imputed HV1 data) as
follows:
Where, PFA100 = PFA100 collagen/epinephrine closure time (in seconds); AUCADP10,
AUCADP5, and AUCADP1 = areas under the curve for ADP at 10, 5, and 1 uM,
respectively; AUCEPI10, AUCEPI1, and AUCEPI0_5 = areas under the curve for
Epinephrine at 10, 1, and 0.5 uM, respectively; AUCCOL5 and AUCCOL2 = areas under
the curve for Collage at 5 and 2 mg/ml, respectively.
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All analyses were performed in in R (version 2.8.1). All statistical tests were two-sided and
a p-value < 0.05 was considered significant.
Results
The baseline characteristics of the three cohorts are described in Table 1. Besides
differences in medications, age was the only significantly different baseline characteristic
between cohorts. As outlined in Figure 1, pre-aspirin (Pre) and the 3 hour post-aspirin (Post)
measurements were made in 52 subjects in HV1, 96 in HV2, and 74 in DM. Per our
selection protocols (described in the Methods), the following numbers of subjects returned
for the Final visit in each cohort: 52 in HV1, 52 in HV2, and 42 in DM.
Construction of the platelet function score (PFS) as a surrogate for non COX1 dependent
platelet function (NCDPF)
We observed strong and significant correlation between various measures of NCDPF made
before and after aspirin exposure in HV1 (Table 2). To condense these measures of platelet
function into a single metric we conducted a PCA on the PFA100 closure time and the
AUCs induced by epinephrine, ADP, and collagen to derive the PFS on all timepoints in
HV1. As anticipated, the PFS was highly correlated with the platelet function measurements
used to construct the PFS, with the weakest correlation with PFA100 and strongest with
epinephrine LTA. (Table 3) To validate the PFS we assessed the correlation between PFS
and platelet function measures in HV2 and DM cohorts. In these cohorts, the PFS was
calculated by taking their platelet function measures and applying the weights derived from
the PCA from HV1. In these validation cohorts, the PFS significantly and strongly
correlated with each measure of NCDPF, with a similar strength and direction as in HV1
(Table 3).
Acute effects of aspirin on COX-1 dependent platelet function
COX-1 dependent platelet function, as assessed by AAA, was effectively suppressed by a
single, 325mg dose of aspirin in all HV2 and DM subjects; the in vitro addition of aspirin
had no further effect on AAA. (Figure 2)
Acute effects and characteristics of aspirin on NCDPF
The main measure of NCDPF in this study, the PFS, was sensitive to the influence of aspirin
as demonstrated by a significant shift in the PFS distribution to lower values (Figure 3):
mean difference in Pre vs. Post PFS, [95% confidence interval] for HV1, HV2, and DM: 3.4
[3.0–3.7], 4.8 [4.5–5.2], 4.2 [3.6–4.8], paired t-test p-value < 0.0001 for all comparisons. In
contrast to the uniform suppression of COX-1 dependent platelet function (Figure 2) after a
single 325mg dose of aspirin, NCDPF persisted and demonstrated wide interindividual
variation (Figure 3). We also found a significant, and strong correlation between the Pre and
Post PFS in all three cohorts (Figure 4, r = 0.77, 0.81, and 0.73 for HV1, HV2, and DM
cohorts, respectively; p <0.0001 for all).
In healthy volunteers, daily aspirin therapy results in a time-dependent shift towards
higher NCDPF
After two weeks of aspirin in HV1, we observed a strong correlation between the Post and
Final PFS values (r = 0.74, p < 0.0001). Despite this high degree of correlation, we observed
that the PFS measured after two weeks of aspirin was shifted higher (mean difference Post
and Final PFS = 0.5, [0.1–0.8], paired t-test p = 0.01) towards pre-aspirin levels of platelet
function. In the HV2 cohort we also observed a similar shift to higher PFS after four weeks
of aspirin (Figure 5A, mean difference between Post and Final PFS = 0.7, [0.2–1.2], paired
t-test p = 0.004). This shift towards higher PFS over time was accompanied by a similar
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trend in most but not all of the individual components of the PFS (epinephrine: paired t-test
p-values: ≤ 0.05 for 10 and 1 uM in HV1 and < 0.008 for all concentrations in HV2; ADP: p
= 0.07 for 10uM in HV1, p = 0.03 for 5uM in HV2; Collagen: p<0.005 for 2uM in HV1 and
p < 0.07 for all concentrations in HV2; PFA100: p = 0.01 for HV1). These observations
demonstrate that there was a significant change in NCDPF induced by aspirin in healthy
volunteers.
Heterogeneity in the change in NCDPF during aspirin exposure depends on initial
response to aspirin
Although on average PFS increased during aspirin exposure in both groups of healthy
volunteers, on inspection of the individual trends in HV2 (Figure 5A) it was apparent that
there was heterogeneity in these trends with some trending to higher Final PFS and others
trending to lower Final PFS values. Stratifying the HV2 cohort based on those that increased
their Final PFS (Figure 5B) vs. those that decreased their Final PFS (Figure 5C)
demonstrated that the Post PFS was significantly different (Post PFS in those that increased
vs. decreased PFS: −1.0 vs. 1.68, t-test p = 0.002) between groups. To better characterize
this heterogeneity, we correlated the change in PFS (Final - Post) and the Post PFS in the
HV1 cohort and found an inverse correlation (r = −0.45, p = 0.001, Figure 6A), suggesting
that the basis for the direction and magnitude of change in PFS during aspirin therapy was
the initial response to aspirin. To validate this observation, we hypothesized that we would
find an inverse correlation in HV2 and DM and again found a pattern in the same direction
and with a greater strength as in the HV1 cohort (HV2: r = −0.54, p < 0.0001, Figure 6B;
DM: r = −0.68, p < 0.0001, Figure 6C). Combining data from all three cohorts, the PFS after
the first dose of aspirin was significantly correlated with the change in PFS during aspirin
therapy (r = −0.59, p-value <0.0001, Figure 6D).
The increase in NCDPF induced by aspirin is not due to uninhibited COX-1
In the HV2 and DM subjects, we found that AAA (median % aggregation = 3.0, range: 0–
7%) and in HV2 serum thromboxane B2 concentration (mean concentration = 0.3, range
0.1–2.0 ng/ml) remained suppressed and did not correlate with the Final PFS (r < 0.2, p >
0.3).
To demonstrate that the change in NCDPF induced by aspirin is not due to uninhibited
COX1, in a subset of subjects (n = 5 HV2 and n = 15 DM subjects) we used the in vitro
addition of aspirin to test if additional aspirin could further reduce NCDPF. We found that
the in vitro addition of aspirin caused no further reduction in NCDPF using epinephrine
0.5uM (mean change aggregation with in vitro aspirin = 2.0%, [−0.8 – 4.8%], paired t-test p
= 0.2), ADP 5uM (mean change = −2.3% [−6.9 – 2.4%], paired t-test p = 0.3), or collagen
2mg/ml (mean change = 1.5%, [−6.9, 10.0], paired t-test p = 0.71).
Discussion
In this study, we utilized a variety of platelet agonists before and after the administration of
aspirin in conjunction with a principal components analysis (PCA) to derive an integrated
measure of non COX-1 dependent platelet function (NCDPF) in a cohort of healthy
volunteers (HV1), which we term the platelet function score (PFS). We first validated the
PFS in two additional cohorts (HV2 and DM) and then employed the PFS to characterize
platelet function with aspirin therapy. The main findings of these investigations are 1)
NCDPF test results are highly correlated and can be efficiently summarized into a single
metric, the PFS; 2) despite complete suppression of COX-1 dependent platelet function with
a 325mg aspirin dose, NCDPF persists and is characterized by wide interindividual
variability that reflects pre-aspirin NCDPF; 3) compared to the response after the first dose,
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daily aspirin therapy predictably results in one of two opposite effects despite continued
suppression of COX-1 or the in vitro addition of aspirin: a) a return of NCDPF towards pre-
aspirin levels or b) a continued decline in NCDPF. Based on these findings we conclude that
the NCDPF response to aspirin is global and dynamic. Although our studies were not
specifically designed to determine the mechanism(s) of this dynamic response, the overall
findings suggest that changes over time may reflect an aspirin independent process.
The concept of a “global” platelet phenotype was first introduced by Yee and colleagues, in
their description of a subset of individuals characterized by heightened platelet aggregation
to submaximal doses of epinephrine.[3] These individuals demonstrated a robust
aggregation response to not only epinephrine, but also other stimuli such as AA, collagen
and ADP, as well as other aspects of platelet function such as adhesion and activation.[23]
Our findings are consistent with those of Yee: We observed a correlation between all test
results (Table 2), serving as the fundamental basis to construct the PFS. Our group was
among the first [24] to use mathematical methods to summarize multiple measures of
platelet function. Ohmori [25], Zufferey and colleagues[26] both utilized factorial analysis
to identify a common “factor” that correlates with multiple measures of platelet function.
Mathias and colleagues used PCA of platelet function measures in a genome-wide linkage
study.[27] Our findings confirm those of prior studies as we identified a common factor, the
PFS, which correlates with multiple measures of platelet function. A corollary to these
observations is found in a recent genome- wide association study (GWAS) of platelet
function where several genetic variants were associated with multiple measures of platelet
function.[28] These GWAS findings suggest that common factors (i.e, genetic variants) may
underlie the response to multiple forms of platelet stimulation. Finally, the strong correlation
between pre- and post-aspirin PFS suggests that variable platelet function on aspirin is a
reflection of underlying, baseline, platelet function. We believe that our ability to identify a
common factor, the PFS, that represents multiple measures of NCDPF strengthens and
extends the concept[3] of a global platelet function phenotype.
Our finding that PFS on aspirin does not correlate with AAA or serum thromboxane B2
further strengthens the hypothesis that the response to aspirin should be considered from two
related but fundamentally distinct perspectives: COX-1 dependent (exemplified by AAA
and serum thromboxane B2) and non COX-dependent (such as ADP, collagen, and
epinephrine induced aggregation) platelet function. Prior studies[13,8,25], have shown that
persistent NCDPF on aspirin is not due to incomplete COX-1 inhibition. Our data highlights
that while COX-1 dependent platelet function can be suppressed by 325mg/day aspirin,
NCDPF on aspirin cannot, and instead may require alternate or additional antiplatelet
therapy. Last, we conclude that the true laboratory “response” to aspirin cannot be based on
a COX-1 dependent test but also requires measures of NCDPF. Accordingly and as
demonstrated by Frelinger and colleagues, the true clinical response to aspirin (i.e,
protection from cardiovascular events) is a function COX-1 dependent and non COX1
dependent platelet function in individuals using aspirin for cardioprotection[9].
In our comparisons of NCDPF response to aspirin after single vs. repeated doses we found a
strong and significant correlation in the PFS. This is consistent with current thinking that
pre-aspirin platelet function is reproducible within individuals[3] and extends this position
further to the platelet function response to aspirin. Despite this high level of correlation,
there was a shift towards higher PFS values after repeated doses of aspirin (Figure 5) in
most healthy individuals. A simple explanation for such a shift would have been
nonadherence with aspirin[29]. After a systematic search through the use of medication
diaries and pill counts, we could not find any evidence for nonadherence. Further, we tested
for nonadherence [30] using COX-1 dependent platelet function assays which showed
complete inhibition of aggregation after repeated aspirin dosing. Most importantly, because
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in vitro aspirin did not further reduce NCDPF, we feel confident that neither nonadherence
nor unsuppressed COX-1 activity were the causes for the observed changes in NCDPF.
Although the mechanism for this shift in NCDPF is not yet known, it was seen across all
agonists and most apparent using epinephrine as an agonist, a finding which suggests that
epinephrine- induced aggregation is a marker of global platelet function[3,5,14]. Our study
adds a dimension to prior observations with low dose aspirin by demonstrating that
decreasing response over time in some subjects occurs despite the use of high dose aspirin
and cannot be overcome in vitro even with high concentrations of aspirin [18]. Accordingly,
although NCDPF can be used to measure the effect of aspirin, we believe the observed
changes in NCDPF over time are due to an aspirin insensitive mechanism.
The direction and magnitude of the change in platelet function is not constant, but instead,
varies as a function of the initial response to aspirin. The consistent, strong, and inverse
correlation between the change in PFS induced by aspirin (Figure 6D) demonstrates that for
a given subject, NCDPF is regulated and can respond to drug therapy in a time- and platelet
function dependent manner. To illustrate the magnitude of the changes in NCDPF over time,
for each unit change in PFS, there is a 7% difference in the maximal aggregation with 10uM
epinephrine, a 3% difference with 10uM ADP, and a 5% difference with 5mg/ml collagen.
Since the magnitude of change in PFS ranged from −5.0 to 5.0 (i.e. y-axis in Figure 6),
changes in NCDPF, in some subjects, may lead to a clinically important difference in overall
platelet function. Although the mechanism is unknown, possible explanations include (1)
aspirin having a direct effect on the megakaryocyte or on a feedback loop between
circulating platelets and megakaryocytes to regulate the level of overall platelet function;(2)
a homeostatic mechanism to restore platelet function during antiplatelet therapy in healthy
individuals, while for those with heightened platelet function[3] there may be a “reserve” of
platelet function that can be further inhibited with prolonged aspirin therapy. Consistent with
the latter hypothesis, a majority (67%) of diabetics in our study - a group characterized by
heightened platelet function[31] - demonstrated a decrease in NCDPF during prolonged
aspirin therapy. Therefore in individuals with heightened platelet function, whether due to
an inherent difference[3] or a diseased state such as diabetes, aspirin induces an initial, acute
decline in NCDPF followed by a continued slower decline over time. In contrast those with
low/normal levels of NCDPF also experience an acute decline; however, their platelet
function is characterized by a return towards pre-aspirin levels over time.
There are several limitations of our study that deserve consideration. First, because our study
design focused on subjects in the upper/lower quartiles of NCDPF in HV2 and DM after the
first dose of aspirin, the observations may be due to a “regression to the mean” phenomenon.
However, in the HV1 cohort we did not focus on the extremes of the platelet function
distribution and instead took an unselected sample. Therefore regression to the mean may
account for the greater magnitude of correlation in the HV2 and DM cohorts compared to
HV1, however, it is unlikely to explain the overall observation seen in all three cohorts. A
true test would be to compare single-dose responses in NCDPF to aspirin separated by
several weeks with the multi-dose data presented in these studies. Second, because we
performed a large number of LTA measurements, the PFS may be biased towards these
measures over the PFA100. The correlation between PFS and PFA100 was relatively weak
and is consistent with a potential bias towards LTA measurements. Alternatively, since there
are many other factors (e.g. von Willebrand factor, platelet count, and hematocrit [32]) that
also influence PFA100 test results, the PFS may only capture that component of the PFA100
test that relates to platelet function. Finally, we did not assess COX-1 dependent platelet
function in HV1; however, we did measure COX-1 dependent platelet function with AAA
and/or assayed serum thrombaxane in the HV2 and DM cohorts.
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In summary, non COX-1 dependent platelet function is a global platelet phenotype that can
be summarized using the PFS. The PFS in our studies of healthy volunteers and diabetics
enable us to conclude that the platelet function response to aspirin is dynamic and should be
based on non-COX1 dependent measures of platelet function made after several weeks of
daily aspirin therapy. Future studies investigating the mechanisms of this response may
uncover novel molecular pathways that are critical for the regulation of platelet function and
the response to antiplatelet therapies.
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Fig. 1. Study overview
An overview study flow for the two healthy volunteer cohorts (HV1 and HV2) and diabetic
cohort (DM). All subjects had platelet function measures (detailed in Methods) made before
(Pre) and 3 hours after (Post). All HV1 subjects and selected HV2 and DM subjects
continued with daily aspirin therapy and returned for a Final assessment of platelet function
made 3–5 hours after the final aspirin dose. * = see selection protocol in Methods
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Fig. 2. COX-1 dependent platelet function with aspirin
Arachidonic acid-induced platelet aggregation before (Pre), 3 hours after 325mg aspirin by
mouth without in vitro aspirin (Post), and 3 hours after 325mg aspirin by mouth with in vitro
aspirin (Post + ASA) % aggregation on Y axis; AA arachidonic acid concentration =
0.5mM; in vitro aspirin concentration = 53 uM
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Fig. 3. Distributions of Platelet Function Score (PFS)
Histograms of platelet function score (PFS) for two cohorts of healthy volunteers (HV1 and
HV2) and a cohort of diabetics (DM), before (Pre, shaded) and 3 hours after a single 325mg
aspirin dose (Post, unshaded). The curves represent the probability density functions for the
Pre (dashed) and Post (solid) PFS distributions, demonstrate the shift towards lower platelet
function with a single dose of aspirin, and that variable pre-aspirin platelet function is
largely retained post-aspirin
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Fig. 4. Pre aspirin PFS predicts Post aspirin PFS
Relationship between non COX-1 dependent platelet function measured pre-aspirin (Pre
PFS, on x-axis) and the immediately after the first 325mg aspirin dose (Post PFS, on y-axis)
in two cohorts of healthy volunteers (A and B) and diabetics (C). Although there is a strong
correlation between pre- and post-PFS in each cohort, the effect of aspirin in each cohort is
demonstrated by individual points lying below the solid line (slope = 1, intercept = 0)
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Fig. 5. Temporal changes in PFS during daily aspirin therapy
Non COX1 dependent platelet function as assessed by PFS at three time points in HV2
cohort (A): pre-aspirin (Pre), after the first 325mg dose of aspirin (Post), and after 4 weeks
of 325mg/day aspirin (Final). The HV2 cohort was then divided based on an increase (B) or
decrease (C) in PFS over time.
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Fig. 6. Time-dependent change in PFS on aspirin is a function of acute response
Change in platelet function score (PFS) defined as Final - Post PFS (y-axis) vs. Post PFS (x-
axis) in HV1 cohort (A), HV2 cohort (B), diabetics (DM, C), and in all subjects (D). Open
circles = healthy volunteers. Crosses = diabetics. The magnitude and direction of the change
in PFS over time is inversely proportional to the initial response to aspirin in each cohorts
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Table 1
Baseline characteristics
HV1 (n= 52 ) HV2 (n = 96) DM (n =74)
Age (mean +/− SD, years) 31 ± 9 43 ± 9* 55 ± 11*
Female (n) 26 59 46
Race (n, white/black/other) 36/9/7 60/32/4 40/30/4
Medications (n)
 • OCP 5 6 0
 • Insulin - - 9
 • Oral agents - - 59
 • Diet control - - 6
 • Anti-HTN - - 49
 • Lipid lowering - - 37
*p < 0.001 for comparison with HV1; OCP = oral contraceptive pills; HTN = hypertensive
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